PIK3CA and breast cancer: In breast cancer patients, a recent study suggests patients with PIK3CA mutations may actually have a more favorable prognosis [32], and that tumors with PIK3CA mutations irrespective of cancer type might have improved response rates to PI3K-directed therapies.